CN112007106B - 一种提高免疫力的发酵组合物及其制备方法 - Google Patents
一种提高免疫力的发酵组合物及其制备方法 Download PDFInfo
- Publication number
- CN112007106B CN112007106B CN202010895629.2A CN202010895629A CN112007106B CN 112007106 B CN112007106 B CN 112007106B CN 202010895629 A CN202010895629 A CN 202010895629A CN 112007106 B CN112007106 B CN 112007106B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese
- fermentation
- freeze
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000036039 immunity Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 20
- 238000000855 fermentation Methods 0.000 claims abstract description 60
- 230000004151 fermentation Effects 0.000 claims abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 43
- 239000000843 powder Substances 0.000 claims description 62
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 54
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 54
- 239000002994 raw material Substances 0.000 claims description 31
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 30
- 235000008434 ginseng Nutrition 0.000 claims description 30
- 244000061520 Angelica archangelica Species 0.000 claims description 29
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 29
- 244000248825 Peltandra virginica Species 0.000 claims description 29
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 29
- 235000008599 Poria cocos Nutrition 0.000 claims description 29
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims description 29
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 29
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 27
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 27
- 229960003080 taurine Drugs 0.000 claims description 27
- 229940026510 theanine Drugs 0.000 claims description 27
- 241000234435 Lilium Species 0.000 claims description 26
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 22
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 22
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 22
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 22
- 238000000227 grinding Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 14
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 14
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 14
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 14
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 238000013329 compounding Methods 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- 239000012535 impurity Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 108010059892 Cellulase Proteins 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 11
- 108010059820 Polygalacturonase Proteins 0.000 claims description 11
- 239000004365 Protease Substances 0.000 claims description 11
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 11
- 229940106157 cellulase Drugs 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 11
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 240000005717 Dioscorea alata Species 0.000 claims description 5
- 235000002723 Dioscorea alata Nutrition 0.000 claims description 5
- 235000005362 Dioscorea floribunda Nutrition 0.000 claims description 5
- 235000004868 Dioscorea macrostachya Nutrition 0.000 claims description 5
- 235000005361 Dioscorea nummularia Nutrition 0.000 claims description 5
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 claims description 5
- 235000004879 dioscorea Nutrition 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 239000000413 hydrolysate Substances 0.000 claims description 5
- 241000208340 Araliaceae Species 0.000 claims 6
- 208000025721 COVID-19 Diseases 0.000 abstract description 22
- 241000711573 Coronaviridae Species 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 9
- 208000015181 infectious disease Diseases 0.000 abstract description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 7
- 230000002924 anti-infective effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 240000004371 Panax ginseng Species 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019985 fermented beverage Nutrition 0.000 description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 235000007056 Dioscorea composita Nutrition 0.000 description 3
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 3
- 240000002624 Mespilus germanica Species 0.000 description 3
- 235000017784 Mespilus germanica Nutrition 0.000 description 3
- 235000000560 Mimusops elengi Nutrition 0.000 description 3
- 235000007837 Vangueria infausta Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000021552 granulated sugar Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000934230 Anoectochilus roxburghii Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000131458 Elsholtzia Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种辅助预防COVID‑19的发酵组合物,该组合物适于广大社会群众并具有较好的人群接受度,能够提高大众人群免疫力和抗感染能力,具有较好辅助预防COVID‑19感染的效果。本发明的中药组合物具有协同增效的效果,本发明通过增加RAW267.4细胞增殖,并且抑制IL‑2、IL‑6和TNF‑α的释放,从而提高机体的免疫力,通过提高免疫力发挥抗COVID‑19感染的作用,是一种理想的辅助预防新冠病毒感染的发酵组合物。
Description
技术领域
本发明属于中药制剂领域,具体涉及一种辅助预防COVID-19的发酵组合物及其制备方法。
背景技术
新型冠状病毒( Severe Acute RespiratorySyndromeCoronavirus 2,SARS-CoV- 2) 感染引起的新型冠状病毒肺炎( Corona Virus Disease 2019,COVID-19) 是一种急性感染性肺炎,初期以发热、干咳、气促、乏力为主要症状,重症患者则出现呼吸困难,进一步发展为急性呼吸窘迫症、脓毒症休克及多器官功能衰竭等,甚至死亡,严重威胁着人们的健康安全。
COVID-19西医治疗尚无确切有效的方法,西药常规就是以抗病毒、抗感染及增强免疫力等对症支持治疗为主,包括氯喹、瑞德西韦在内的抗病毒药其疗效也待进一步评价,且其临床观察用药的副作用较大。
许多中医药学者对新型冠状病毒肺炎病因病机进行了诸多有益的探索,分别从燥邪、热邪、阴虚、湿邪等方面进行了阐释并加以治疗,大大提高了中医的参与率和有效率;中医理论认为本病属于中医学“寒湿疫”,其直接病因是感受“疫戾之气”。本病在病性上属于阴病,是以伤阳为主线。早期以寒湿闭郁脾肺伤阳为主,中期以湿热遏阳为主,其治法以温散寒湿通阳为原则,宣通中上二焦,兼以透热袪邪;若失治误治,病邪则传入阳明化燥化热,治疗原则应在温散寒温基础上加大清热解毒力度,或以清热解毒通腑为主;祛湿透邪、健脾宣肺通阳贯穿始终。后期及恢复期以阳气虚损为主,治法以温补脾肾之阳为原则,温通中下焦,使先后天均得以固护,此乃治本之举。
专利CN111494469A要求保护一种抗病毒药用组合物,含有广藿香4-14份、苍术9-28份、香薷5-18份、艾叶11-33份、丁香0.1-3份和薄荷2-10份。该组合物对新冠病毒具有一定的治疗效果,但是该药物组合物适用对象是已感染新冠病毒患者,并不适用于非感染人群的预防新冠病毒;
专利CN111544442A中请求保护了芦丁作为冠状病毒广谱抑制剂,但是并未公开具体的配方。
专利CN111529625A要求保护了一种可预防复工人群感染新冠肺炎的中药配方,原料包括太子参、麦冬、荷叶、大青叶、牛蒡子、升麻、连翘、赤芍、甘草、绿茶,在提高机体抵抗力的同时,有效缓解发热、咳嗽、咽痛、乏力、气短、倦怠等症状,适用于正常人群的日常保健。但是该产品直接将各中药制备成袋泡茶,适口性差,不易被普通人群接受。
经检索,目前还未见报道一种能够让大众群众乐于接受的辅助预防COVID-19的制剂。
综上所述,提供一种易于让社会大众人群接受的辅助预防新冠病毒的发酵组合物很有必要,能够带来显著的社会效益。
发明内容
鉴于以上背景技术提到的缺陷,本发明旨在添补辅助抗辅助预防COVID-19制剂领域的空白,提供一种辅助预防COVID-19的制剂,提供一种适于广大社会群众并具有较好的人群接受度,能够提高大众人群免疫力和抗感染能力,具有较好辅助COVID-19感染预防效果的发酵组合物。
具体地,本发明提供一种辅助预防COVID-19的发酵组合物,其特征在于,所述发酵组合物包括中药原料百合、炒山药、当归、大枣、茯苓和人参。
所述的辅助预防COVID-19的发酵组合物,所述中药原料经植物乳杆菌和发酵乳杆菌组成的复合菌发酵处理。
所述的辅助预防COVID-19的发酵组合物,所述原料包括百合5-20份、炒山药5-20份、当归3-15份、大枣2-10份、茯苓2-10份、人参1-3份。
所述的辅助预防COVID-19的发酵组合物,所述原料包括百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份。
所述的辅助预防COVID-19的发酵组合物,所述发酵组合物进一步包含新资源食品原料,所述新资源食品含有牛磺酸、蛋白粉、谷氨酰胺、低聚异麦芽糖、茶氨酸。
所述的辅助预防COVID-19的发酵组合物,其特征在于新资源食品的配比为:牛磺酸:蛋白粉:谷氨酰胺:低聚异麦芽糖:茶氨酸=1-50: 1-50: 1-50: 1-50: 1-50。
本发明还提供了一种辅助预防COVID-19的发酵组合物,原料包括百合5-20份、炒山药5-20份、当归3-15份、大枣2-10份、茯苓2-10份、人参1-3份,牛磺酸1-50份、蛋白粉1-50份、谷氨酰胺1-50份、低聚异麦芽糖1-50份、茶氨酸1-50份,其中,中药原料百合、炒山药、当归、大枣、茯苓、人参经植物乳杆菌和发酵乳杆菌组成的复合菌发酵处理步骤。
本发明还提供了一种辅助预防COVID-19的发酵饮料组合物,原料包括百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份、白砂糖20份、山梨酸钾0.05份,其中,中药原料百合、炒山药、当归、大枣、茯苓、人参经植物乳杆菌和发酵乳杆菌组成的复合菌发酵处理步骤。
本发明还提供了一种辅助预防COVID-19的发酵组合物的制备方法,其特征在于按如下步骤进行:
S1:选择百合5-20份、炒山药5-20份、当归5-20份、大枣2-10份、茯苓2-10份、人参1-3份为原料,除杂后使用超微粉碎机进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水50-70份,然后加入纤维素酶、果胶酶、蛋白酶复合酶液水解,得到中药酶解液;
S3:将中药酶解液加入植物乳杆菌、发酵乳杆菌复合发酵,得到发酵液;
S4:发酵液经离心取上清液,上清液经冷冻干燥得中药冻干燥粉;
S5:在中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
所述的发酵组合物的制备方法,所述方法进一步包含如下步骤:
S6:将发酵组合物加入辅料白砂糖20份、防腐剂山梨酸钾0.05份制备成发酵饮料产品;
或将发酵组合物加入淀粉100份、羟丙基纤维素20份、交联羧甲基纤维素钠10份制备成片剂;
或将发酵组合物加入玉米淀粉80份、滑石粉10份、交联纤维素5份制备成胶囊剂;
或加入蔗糖30、糊精10份和可溶性淀粉80份制备成颗粒冲剂;
本发明的发酵组合物可制备成的剂型并不受饮料、胶囊剂、颗粒冲剂和片剂的限制,常规的其他剂型均可实现本发明的技术效果。
本发明提供一种辅助预防COVID-19的发酵组合物,该组合物适于广大社会群众并具有较好的人群接受度,能够提高大众人群免疫力和抗感染能力,具有较好辅助预防COVID-19感染效果。
并且,本发明的中药组合物具有协同增效的效果,本发明通过增加RAW267.4细胞增殖,并且抑制IL-2、IL-6和TNF-α的释放,从而提高机体的免疫力,通过提高免疫力发挥抗COVID感染的作用,是一种理想的辅助预防新冠病毒感染的发酵组合物。
具体实施方式
实施例1
原料选择:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份;制备方法按如下步骤进行:
S1:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水50-70份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:将中药酶解液加入质量体积比为1%植物乳杆菌、发酵乳杆菌复合发酵,得到发酵液;
S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S5:中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
实施例2
原料选择:百合20份、炒山药20份、当归15份、大枣10份、茯苓10份、人参3份,牛磺酸50份、蛋白粉50份、谷氨酰胺50份、低聚异麦芽糖50份、茶氨酸50份;制备方法按如下步骤进行:
S1:百合20份、炒山药20份、当归15份、大枣10份、茯苓10份、人参3份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水100-130份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:将中药酶解液加入质量体积比为1%的植物乳杆菌、发酵乳杆菌复合发酵菌进行发酵处理,得到发酵液;
S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S5:中药冻干粉中加入牛磺酸50份、蛋白粉50份、谷氨酰胺50份、低聚异麦芽糖50份、茶氨酸50份,按比例复配,混合均匀得发酵组合物。
实施例3
原料选择:百合5份、炒山药5份、当归3份、大枣2份、茯苓2份、人参1份,牛磺酸1份、蛋白粉1份、谷氨酰胺1份、低聚异麦芽糖1份、茶氨酸1份;制备方法按如下步骤进行:
S1:百合5份、炒山药5份、当归3份、大枣2份、茯苓2份、人参1份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水30-50份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:将中药酶解液加入质量体积比为1%的植物乳杆菌、发酵乳杆菌复合发酵菌进行发酵处理,得到发酵液;
S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S5:中药冻干粉中加入牛磺酸1份、蛋白粉1份、谷氨酰胺1份、低聚异麦芽糖1份、茶氨酸1份,按比例复配,混合均匀得发酵组合物。
对比例1
原料选择:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份;制备方法按如下步骤进行:
S1:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水50-70份,加入质量体积比为1%植物乳杆菌、发酵乳杆菌复合发酵菌进行发酵处理,得到发酵液;
S3:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S4:中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
对比例2
原料选择:枸杞子9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份;制备方法按如下步骤进行:
S1:枸杞子9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水30-50份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:将中药酶解液加入质量体积比为1%的植物乳杆菌、发酵乳杆菌复合发酵菌进行发酵处理,得到发酵液;
S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S5:中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
对比例3
原料选择:百合9份、薏仁9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份;制备方法按如下步骤进行:
S1:枸杞子9份、薏仁9份、当归6份、大枣3份、茯苓3份、人参1份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水30-50份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:将中药酶解液加入质量体积比为1%的植物乳杆菌、发酵乳杆菌复合发酵菌进行发酵处理,得到发酵液;
S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S5:中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
对比例4
原料选择:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份;制备方法按如下步骤进行:
S1:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水50-70份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:酶解液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S4:中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
实施例5
原料选择:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份;制备方法按如下步骤进行:
S1:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份为主要原料,除杂后进行超微粉碎处理;
S2:将超微粉碎获得的中药超微粉加入水50-70份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:将中药酶解液加入质量体积比为1%植物乳杆菌、发酵乳杆菌复合发酵,得到发酵液;
S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;
S5:中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
S6:将发酵组合物加入辅料白砂糖20份、防腐剂山梨酸钾0.05份制备成发酵饮料产品。
本发明得到的发酵饮料组合物口感甜润,没有中药的苦涩口感,适合广大人群接受,具有较好的社会人群接受度。
试验例1
实验中所用的动物、动物细胞、试剂均来自商业化购买。
小鼠巨噬细胞RAW264.7 的培养RAW264.7 细胞加入新鲜的含10%胎牛血清的DMEM培养基,用毛细管充分吹打均,制备单细胞悬,并用血细胞计数板计数。分别按每孔1000个、2000 个、4000 个的细胞数量接种于96 孔细胞培养板中,用10 %胎牛血清的DMEM 培养基补充至每孔100 μL,在37 ℃、饱和湿度、5%CO2 培养箱中静置培养。
称取发酵组合物5mg 溶于5 mL空白DMEM 高糖培养基,得到浓度为1 mg/ml的母液,从1 mg/ml稀释100 倍,得到1 ug/ml,继续稀释10 倍,得到1 000ng/ml,依次稀释10 倍和100 倍,得到100 和10 ng/ml,取对数期生长的细胞以每孔1×105 接种于96 孔的细胞培养板中,24 h 细胞贴壁后,通过CCK-8 实验检测:在96 孔板中接种细胞悬液,将培养板放在培养箱(37 ℃,5 % CO2 的条件下)预培养,4 h 后向每孔加入10 μL 的CCK-8 溶液,将培养板在培养箱内孵育2 h 后,用酶标仪在450 nm 处测定吸光度(OD),连续重复7 d,测定每天的OD 值,得出各个密度的生长曲线。根据寇氏法计算发酵组合物的半抑制浓度,依据IC50 设定10,100,1000 ng·mL-13 个给药浓度进行实验。
实验分组及给药将对数生长期的RAW264.7 细胞分别按每孔6×106 个培养接种到6 孔细胞培养板中,随机分为空白对照组,LPS 模型组(10 μg·mL-1的LPS),中药冻干粉低、中、高剂量组(10,100,1000 ng·mL-1)。加入药物后将细胞放入CO2 培养箱中孵育2 h,再每孔加入10 μg·mL-1 LPS 继续培养10 h,备用1.7 ELISA 法测定IL-1、IL6、TNF-α的含量用磷酸缓冲盐溶液(PBS)将细胞清洗,然后用RIPALysis Buffer(RIPA 裂解液)裂解,使用蛋白定量试剂盒作蛋白定量,依照酶联免疫吸附测定(ELISA)法,按照抗原包被、加入样品、加入酶标抗体、加入底物显色、最后终止反应等步骤,使用瑞士TECAN 多功能酶标仪在450 nm 处测定OD 值,建立标准曲线,计算出IL-6、IL-10、TNF-α释放量。
发酵组合物对LPS 诱导的RAW264.7 细胞炎性因子表达的影响见表1。发酵组合物
对LPS 诱导RAW264.7 细胞释放的IL-1、IL-6、TNF-α均有不同程度的抑制作用,其中与空白
对照组比较,LPS 模型组的IL-1、IL-6、TNF-α释放均显著增高(P < 0.01);而对比例1-3则
明显较实施例1-3结果较差,这暗示了本发明的组合物具有一定的协同增效作用;对比例1
采用了发酵而未采用酶解步骤,而对比例4采用了酶解而未采用发酵步骤,结果显示,对比
例1的IL-1、IL-6和TNF-α的释放量显著低于对比例4,和实施例1-2相当,这提示了发酵工艺
是必须的,而酶解步骤并不是必须步骤;各组间比较差异均有统计学意义(P < 0.05,P <
0.01)。
组别 | IL-1 ng/L | IL-6 ng/L | TNF-αng/L |
空白对照 | 36.51±10.26 | 30.61±6.85 | 28.53±8.52 |
LPS模型组 | 153.03±15.33 | 126.58±8.20 | 60.35±15.26 |
实施例1 | 58.62±15.62 | 53.51±9.47 | 35.07±12.95 |
实施例2 | 63.04±22.12 | 58.74±8.06 | 33.51±12.04 |
对比例1 | 72.54±16.07 | 75.98±11.58 | 40.25±20.67 |
对比例2 | 112.37±25.64 | 101.25±18.56 | 55.36±12.41 |
对比例3 | 108.30±15.75 | 95.08±14.30 | 56.23±18.98 |
对比例4 | 99.75±16.58 | 83.56±12.14 | 50.79±7.65 |
实验例2
参考文献“郑小香,金线莲多糖对小鼠脾淋巴细胞和巨噬细胞RAW体外免疫活性研究”第二章中的实验方法,采用小鼠实验,将文献中的金线莲多糖换成本发明的实施例1的发酵组合物,发现发酵组合物在50-800ug/ml浓度范围时,OD值较空白对照组提高17.07%,说明实施例1的发酵组合物能促进小鼠RAW267.4细胞增殖。
综上所述,本发明通过增加RAW267.4细胞增殖,并且抑制IL-2、IL-6和TNF-α的释放,从而提高机体的免疫力,通过提高免疫力发挥抗COVID感染的作用,是一种理想的辅助预防新冠病毒感染的发酵组合物。
本发明结合实施例作进一步的说明,但不能用来限制本发明的保护范围,对于药物的其他范围或其他药物的具体实施方式,可参照本发明的技术原理以及实施例的操作来实施,仍在本发明的保护范围内。
Claims (3)
1.一种提高免疫力的发酵组合物,其特征在于,原料为百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份,牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份;制备方法按如下步骤进行:S1:百合9份、炒山药9份、当归6份、大枣3份、茯苓3份、人参1份为主要原料,除杂后进行超微粉碎处理;S2:将超微粉碎获得的中药超微粉加入水50-70份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;S3:将中药酶解液加入质量体积比为1%植物乳杆菌、发酵乳杆菌复合发酵,得到发酵液;S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;S5:中药冻干粉中加入牛磺酸15份、蛋白粉15份、谷氨酰胺15份、低聚异麦芽糖15份、茶氨酸15份,按比例复配,混合均匀得发酵组合物。
2.一种提高免疫力的发酵组合物,其特征在于,原料为百合20份、炒山药20份、当归15份、大枣10份、茯苓10份、人参3份,牛磺酸50份、蛋白粉50份、谷氨酰胺50份、低聚异麦芽糖50份、茶氨酸50份;制备方法按如下步骤进行:S1: 百合20份、炒山药20份、当归15份、大枣10份、茯苓10份、人参3份为主要原料,除杂后进行超微粉碎处理;S2:将超微粉碎获得的中药超微粉加入水100-130份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;S3: 将中药酶解液加入质量体积比为1%的植物乳杆菌、发酵乳杆菌复合发酵菌进行发酵处理,得到发酵液;S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉S5:中药冻干粉中加入牛磺酸50份、蛋白粉50份、谷氨酰胺50份、低聚异麦芽糖50份、茶氨酸50份,按比例复配,混合均匀得发酵组合物。
3.一种提高免疫力的发酵组合物,其特征在于,原料为百合5份、炒山药5份、当归3份、大枣2份、茯苓2份、人参1份,牛磺酸1份、蛋白粉1份、谷氨酰胺1份、低聚异麦芽糖1份、茶氨酸1份;制备方法按如下步骤进行:S1:百合5份、炒山药5份、当归3份、大枣2份、茯苓2份、人参1份为主要原料,除杂后进行超微粉碎处理;S2:将超微粉碎获得的中药超微粉加入水30-50份,然后加入适量纤维素酶、果胶酶、蛋白酶复合酶进行酶解处理,得到中药酶解液;
S3:将中药酶解液加入质量体积比为1%的植物乳杆菌、发酵乳杆菌复合发酵菌进行发酵处理,得到发酵液;S4:发酵液经离心取上清液,经冷冻干燥得中药冻干燥粉;S5:中药冻干粉中加入牛磺酸1份、蛋白粉1份、谷氨酰胺1份、低聚异麦芽糖1份、茶氨酸1份,按比例复配,混合均匀得发酵组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010895629.2A CN112007106B (zh) | 2020-08-31 | 2020-08-31 | 一种提高免疫力的发酵组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010895629.2A CN112007106B (zh) | 2020-08-31 | 2020-08-31 | 一种提高免疫力的发酵组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112007106A CN112007106A (zh) | 2020-12-01 |
CN112007106B true CN112007106B (zh) | 2021-04-23 |
Family
ID=73502661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010895629.2A Active CN112007106B (zh) | 2020-08-31 | 2020-08-31 | 一种提高免疫力的发酵组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112007106B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102503431B1 (ko) * | 2021-02-09 | 2023-02-27 | 주식회사 진생바이팜 | 흑삼을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 |
CN113057244A (zh) * | 2021-04-29 | 2021-07-02 | 山东省现代中药研究院有限公司 | 一种具有免疫调节作用的压片糖果制备工艺 |
CN114632121B (zh) * | 2022-02-24 | 2023-08-22 | 山西广誉远国药有限公司 | 一种中药露酒的制备方法及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108785331A (zh) * | 2018-08-10 | 2018-11-13 | 泰安大凡神农生物有限公司 | 一种具有气血双补的组合物及其制备方法和应用 |
-
2020
- 2020-08-31 CN CN202010895629.2A patent/CN112007106B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108785331A (zh) * | 2018-08-10 | 2018-11-13 | 泰安大凡神农生物有限公司 | 一种具有气血双补的组合物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
乳酸菌发酵山药饮料的研究;檀子贞等;《食品科技》;20010131(第01期);第54页左栏倒数第2段至右栏7段 * |
功能型山药红枣复合饮品的研制;张冠群等;《河南农业》;20171130(第33期);第50页左栏第2段至中栏第3段 * |
Also Published As
Publication number | Publication date |
---|---|
CN112007106A (zh) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112007106B (zh) | 一种提高免疫力的发酵组合物及其制备方法 | |
WO2012165843A2 (ko) | 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
CN108653574B (zh) | 益生菌发酵的抗病毒组合物及其制备方法和应用 | |
CN104922586B (zh) | 一种防治鸡球虫病的益生菌发酵中药制剂的制备及其应用 | |
CN117487683A (zh) | 具有抗幽护胃和消食化积功效的益生菌组合物及其应用 | |
WO2022057360A1 (zh) | 一种用于冬季防治呼吸道疾病的药物组合物 | |
CN113616747A (zh) | 一种感染性疾病康复用的中药组合物及其用途 | |
CN109420046A (zh) | 一种中草药组方制备防治猪高热病药物的方法 | |
CN105878554A (zh) | 一种益生菌发酵八珍汤组合物及其制备方法和应用 | |
KR100527602B1 (ko) | 마과, 씀바귀 및 고들빼기의 추출물을 함유한 복합생약바이러스성 간질환 치료용 조성물 | |
EP3295950A1 (en) | Use of ginseng extract, ginsenoside and ginsenoside derivative in the preparation of medicine or health care product for treating cytomegalovirus infection disorders | |
CN114712453A (zh) | 一种中药组合物在抗病毒、保护脏器、提高免疫力药物中的应用 | |
CN108186866B (zh) | 金贝口服液在抗病毒中的应用 | |
CN113975357B (zh) | 清肺化痰、消痈排脓、清热利湿的中药组合物及其应用 | |
CN108066350B (zh) | 连翘苷、其衍生物、连翘苷与连翘脂素组合物在制备预防、治疗老年痴呆症药物中的应用 | |
WO2021179881A1 (zh) | 中药组合物在制备用于防治冠状病毒合并肺损伤药物中的应用 | |
CN109568430B (zh) | 一种免疫增强剂的制备方法和应用 | |
CN113499381A (zh) | 中药组合物和/或包含该中药组合物的药物制剂在抗流感病毒中的应用 | |
CN104013650B (zh) | 地衣芽孢杆菌与中药多糖组合物及其制剂 | |
CN109865052A (zh) | 一种具有化痰止咳、抗病毒作用的中药组合物的制备方法 | |
CN114259523B (zh) | 一种中药组合物及其在制备治疗咳嗽变异性哮喘的药物中的用途 | |
CN115919970B (zh) | 一种中药组合物及其在新型冠状病毒感染中的应用 | |
KR100553982B1 (ko) | 마과, 씀바귀 및 고들빼기의 추출물을 함유한 복합생약바이러스성 간질환 치료용 조성물 | |
TWI749286B (zh) | 調節腸道菌群平衡的組合物及其製備方法與應用 | |
CN112263612B (zh) | 一种利用微生物发酵制备一清颗粒的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |